Hepatitis is commonly caused by viruses Hepatitis A, B, and C. Inflammation of the liver can also be caused by alcohol use, environmental toxins, and autoimmune disorders. The global burden of viral hepatitis remains substantial, affecting hundreds of millions of people and contributing significantly to morbidity and mortality worldwide. It is estimated that 10% of the Chinese population in China are carriers of Hepatitis B. Long-standing liver infections caused by Hepatitis B and C and cirrhosis as a result of alcohol abuse or metabolic dysfunction also lead to hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related deaths worldwide, in part because it is often diagnosed at an advanced stage when curative options like surgical resection or transplantation are limited.

 

Since 2015, Nucorion Pharmaceuticals has leveraged technologies licensed from Ligand Therapeutics to develop best-in-class proprietary drugs targeting Hepatitis B and HCC. Nucorion Pharmaceuticals has also started leveraging AI-driven models and crystallography data to improve and expand existing pipeline.